Pharma firms are looking to collaborate with the right delivery device partners as a number of rapidly changing factors across the pharmaceutical landscape converge and create the demand for alternate drug delivery technologies.
Lucy Brake speaks to Mike Rea, CEO of IDEA Pharma, about how he believes real world evidence impacts current development and trials processes, and the ways in which pharma can take best take advantage of all this offers.
Prescription drug bulk purchasing agreements can save patients money but could hinder their health outcomes as a result of reduced access to favourable medicines.
John Leonard, Chief Scientific Officer and Vice-President of AbbVie will leave the company in the coming months after twenty years of service, this is just the latest in a series of senior-level R&D departures in the industry, so is this indicative of wider issues within R&D?
"A successful segmentation plan lets you get the return you expect. You have to do your homework, you have to prepare carefully, know what you're aiming at, who your customer base is, what your strategy is, what your goal is."
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type launches to continue to be the norm within the pharmaceutical industry.
Forceful efforts to thwart generic drug competition in France have landed multinational pharma firm Sanofi in deep water with the country’s Competition Authority, which has just issued a €40.6m ($52.7m) fine for a smear campaign targeted at the company’s rivals several years ago.
Matthew Bonam, Pharmaceutical Projects Director at AstraZeneca and Tim Davis, chief executive of Exco InTouch discuss their collaboration and the virtues of mHealth in combatting chronic obstructive pulmonary disease.
With digital adoption no longer an option, but a must, and the growing influence of customers within the pharma industry, your company needs a comprehensive approach that addresses both digital and customer in a complimentary and comprehensive way…
"Is pharma slow to adopt digital?" If you're still asking yourself this question, or some iteration of it, then I think both you and I already know the answer...
Amy Ohm discusses the importance for patients to be able to share their stories and feelings through what can often be a traumatic time in their lives, as well as the benefits to adherence of providing an outlet for patients during this time.
Petteri Jarkka, Customer Engagement Manager at Janssen Nordic, talks to eyeforpharma about how the company is responding to recent calls for a ‘beyond the pill’ approach, and how they’re working with stakeholders to ‘co-create’ services improve health outcomes.
EU citizens are unable to afford life-saving medication due to ongoing cuts and austerity measures, according to a Member of the European Parliament.
Revision of China’s Good Supply Practice for Pharmaceutical Products took almost three years to finalise, the final product establishing higher standards for quality controls in drug distribution and supply chain management across the region. But is there another ultimate goal?
New findings suggest that if recent steps taken by the CIS countries are seen through to completion, it will revolutionize the pharma landscape, and open up access to medicines in these countries.
Ben Steele talks with Eduardo Tchouhadjian, CEO of E. Tchouhadjian & Associates, about how companies in Latin America are responding to the rise of the ‘smart patient’ and how to use “360-degree marketing” to combat the issue of prescription switching in these fast-growing markets.
